In 2019, Mesoblast Ltd (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategyhttp://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
- Forums
- ASX - By Stock
- Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
MSB
mesoblast limited
Add to My Watchlist
0.15%
!
$1.61

In 2019, Mesoblast Ltd (MSB) plans to work diligently with the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.61 |
Change
-0.003(0.15%) |
Mkt cap ! $2.041B |
Open | High | Low | Value | Volume |
$1.61 | $1.62 | $1.57 | $2.539M | 1.596M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 32001 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.62 | 53286 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 9442 | 1.610 |
18 | 54320 | 1.605 |
15 | 79281 | 1.600 |
13 | 57749 | 1.595 |
13 | 107639 | 1.590 |
Price($) | Vol. | No. |
---|---|---|
1.615 | 63282 | 22 |
1.620 | 64906 | 17 |
1.625 | 69975 | 11 |
1.630 | 87320 | 9 |
1.635 | 90941 | 6 |
Last trade - 11.27am 08/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online